Clinical Trial Diversity: Data Points to Structural, Not Patient-Specific Solutions
Executive Summary
Minorities are more likely to participate in cancer clinical trials than white people, but they are less likely to get the chance to say yes, highlighting the importance of bringing studies to different locations if sponsors are to be successful at increasing diversity.
You may also be interested in...
How Do You Build A Clinical Trial Network Focused On Diversity?
Stakeholders discuss network models, barriers to their creation, and what is needed for them to be successful at PhRMA meeting.
COVID-Era Trial Flexibilities, Equity Focus, Could Be Used To Reshape Cancer Study Enrollment
US FDA is open to keeping COVID-necessitated trial changes that may have had unexpected benefits. The agency is also looking at building on pandemic’s focus on health disparities and inequities to push for more generalizable and inclusive clinical trial designs.
Clinical Trial Diversity Requires Community-Based Research Infrastructure, US FDA’s Woodcock Says
COVID-19 trials could have reached underserved populations better if research infrastructure was in place where people routinely get their health care, acting commissioner Janet Woodcock says; PhRMA is looking to establish a public-private partnership that would build a sustainable community-based infrastructure for clinical research.